The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | An update to the risk stratification of MGUS, SMM, and multiple myeloma
Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN, discusses the updated risk stratification for the diagnosis and management of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). Recent changes include incorporating dynamic alterations into MGUS stratification and adding cytogenetics to SMM risk assessment. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
